These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 18591851)

  • 1. Extreme thrombocytosis--an unusual presentation of inflammatory bowel disease.
    Thachil J
    Intern Med; 2008; 47(13):1255-7. PubMed ID: 18591851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron deficiency generates secondary thrombocytosis and platelet activation in IBD: the randomized, controlled thromboVIT trial.
    Kulnigg-Dabsch S; Schmid W; Howaldt S; Stein J; Mickisch O; Waldhör T; Evstatiev R; Kamali H; Volf I; Gasche C
    Inflamm Bowel Dis; 2013 Jul; 19(8):1609-16. PubMed ID: 23644823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between thrombocytosis and iron deficiency anemia in inflammatory bowel disease.
    Voudoukis E; Karmiris K; Oustamanolakis P; Theodoropoulou A; Sfiridaki A; Paspatis GA; Koutroubakis IE
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1212-6. PubMed ID: 23839158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thorax as an extraintestinal target for inflammatory bowel disease.
    Akpınar EE; Gülhan M; Değertekin H; Ataoğlu Ö
    Tuberk Toraks; 2011; 59(3):312-5. PubMed ID: 22087529
    [No Abstract]   [Full Text] [Related]  

  • 5. Role of 5-aminosalicylate in preventing colorectal cancer.
    Riyaz S; Hamlin J; Everett S
    Am J Gastroenterol; 2011 Sep; 106(9):1720-1; author reply 1721-2. PubMed ID: 21897414
    [No Abstract]   [Full Text] [Related]  

  • 6. An unusual case of extreme thrombocytosis caused by iron deficiency.
    Bergmann K; Bergmann OJ
    BMJ Case Rep; 2020 Jan; 13(1):. PubMed ID: 31919059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current status of new drug development for inflammatory bowel diseases].
    Kohgo Y; Tanabe H; Fujiya M
    Nihon Rinsho; 2012 Feb; 70 Suppl 1():378-82. PubMed ID: 23126121
    [No Abstract]   [Full Text] [Related]  

  • 8. [Primary chemoprevention of colorectal cancer in patients with inflammatory bowel diseases].
    Ioffe AIu
    Lik Sprava; 2005 Jun; (4):45-8. PubMed ID: 16158715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of platelet activation by 5-aminosalicylic acid in inflammatory bowel disease.
    Carty E; MacEy M; Rampton DS
    Aliment Pharmacol Ther; 2000 Sep; 14(9):1169-79. PubMed ID: 10971234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron deficiency generates secondary thrombocytosis and platelet activation in inflammatory bowel disease : the randomized, controlled ThromboVIT trial.
    Zuo L; Li Y; Wang H; Zhu W
    Inflamm Bowel Dis; 2013 Oct; 19(11):E85. PubMed ID: 23962897
    [No Abstract]   [Full Text] [Related]  

  • 11. Beta-glucan, inositol and digestive enzymes improve quality of life of patients with inflammatory bowel disease and irritable bowel syndrome.
    Spagnuolo R; Cosco C; Mancina RM; Ruggiero G; Garieri P; Cosco V; Doldo P
    Eur Rev Med Pharmacol Sci; 2017 Jun; 21(2 Suppl):102-107. PubMed ID: 28724171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: platelets in inflammatory bowel disease--pathogenetic role and therapeutic implications.
    Collins CE; Rampton DS
    Aliment Pharmacol Ther; 1997 Apr; 11(2):237-47. PubMed ID: 9146760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-Aminosalicylates in inflammatory bowel disease: choosing the right dose.
    Qasim A; Seery J; O'Morain CA
    Dig Liver Dis; 2001; 33(5):393-8. PubMed ID: 11529648
    [No Abstract]   [Full Text] [Related]  

  • 14. [5-aminosalicylates and colorectal cancer: preventive role in chronic inflammatory bowel disease?].
    Desreumaux P; Romano O
    Gastroenterol Clin Biol; 2004 May; 28(5):509. PubMed ID: 15243337
    [No Abstract]   [Full Text] [Related]  

  • 15. Mesenteric ischemia is a cause of resistance to treatment in IBD.
    Ibiş M; Ataseven H; Basar O; Yüksel I; Ulker A
    Inflamm Bowel Dis; 2009 Aug; 15(8):1129-30. PubMed ID: 18951366
    [No Abstract]   [Full Text] [Related]  

  • 16. Mesalazine preparations.
    Forbes A; Chadwick C
    Lancet; 1997 Nov; 350(9087):1329. PubMed ID: 9357436
    [No Abstract]   [Full Text] [Related]  

  • 17. [Management of adults presenting with a thrombocytosis].
    Viallard JF
    Rev Med Interne; 2010 Dec; 31 Suppl 3():S333-8. PubMed ID: 21035235
    [No Abstract]   [Full Text] [Related]  

  • 18. 5-Aminosalicylic acid.
    Iida T; Onodera K; Nakase H
    Nihon Rinsho; 2017 Mar; 75(3):392-397. PubMed ID: 30566780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of pharmaceuticals by inflammatory bowel disease patients: a population-based study.
    Metge CJ; Blanchard JF; Peterson S; Bernstein CN
    Am J Gastroenterol; 2001 Dec; 96(12):3348-55. PubMed ID: 11774948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extreme thrombocytosis: what are the etiologies?
    Wiwanitkit V
    Clin Appl Thromb Hemost; 2006 Jan; 12(1):85-7. PubMed ID: 16444439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.